ENSG vs RLAY
Ensign Group vs Relay Therapeutics, Inc. — AI-powered side-by-side comparison
VS
RLAY
Relay Therapeutics, Inc.
65
Buy
| Metric | ENSG | RLAY |
|---|
| AI Score |
69
|
65
|
| Price |
$180.10
|
$20.00
|
| P/E Ratio |
27.43×
|
-12.73×
|
| ROE |
15.4%
|
-48.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
-566.6%
|
| Debt / Equity |
0.92×
|
0.03×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
66.0
|
| Beta |
0.694
|
1.704
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus RLAY.
ENSG leads by 4 points.
ENSG scores 69/100 (Buy) versus RLAY at 65/100 (Buy).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
RLAY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is roe of only -42.3% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -42.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical